Clinical Trials Logo

Testicular Yolk Sac Tumor clinical trials

View clinical trials related to Testicular Yolk Sac Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT03426865 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Role of Axumin PET Scan in Germ Cell Tumor

TESTPET
Start date: March 1, 2018
Phase:
Study type: Observational

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

NCT ID: NCT01434355 Completed - Clinical trials for Childhood Malignant Ovarian Germ Cell Tumor

DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Start date: November 1, 2011
Phase:
Study type: Observational

This research trial studies deoxyribonucleic acid (DNA) samples from younger patients with germ cell tumor and their parents or siblings. Studying samples of tumor tissue and saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

NCT ID: NCT00467051 Completed - Clinical trials for Recurrent Ovarian Germ Cell Tumor

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Start date: November 5, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT00060372 Completed - Clinical trials for Stage IV Breast Cancer

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.